Peptide News Digest

#Menopause

3 stories

Industry · View digest

AbCellera Prices Oversubscribed $200 Million Public Equity Offering to Fund Clinical Program ABCL635 (Vasomotor Symptoms) and Antibody Pipeline

AbCellera Biologics (NASDAQ: ABCL) announced Wednesday August 12, 2026 the pricing of an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 per pre-funded warrant, for aggregate gross proceeds of approximately $200 million. Net proceeds of approximately $187 million are targeted to advance clinical development of lead program ABCL635 (an antibody-based candidate for vasomotor symptoms of menopause and related endocrine indications) plus additional immunology and oncology candidates. The offering closed August 14. AbCellera is a clinical-stage biotechnology company focused on discovering first-in-class antibody-based medicines in endocrinology, women's health, immunology, and oncology using its integrated antibody-discovery platform. Not a peptide company, but the offering is included here because AbCellera's platform overlaps with peptide-discovery approaches in the same discovery-to-clinical translation ecosystem, and the H2 2026 biotech financing window (which has already delivered Parabilis's $670M peptide IPO, Kardigan's $400M+ cardio IPO, and now AbCellera's $200M follow-on) reflects continued institutional appetite for platform-derived biologics.

Clinical Trials · View digest

Novo Nordisk Pre-EASL 2026 Data Drop (May 19): ESSENCE Liver Safety Analysis Confirms Favorable Hepatic Profile for Semaglutide 2.4 mg in MASH

Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.

Clinical Trials · View digest

Novo Nordisk ECO 2026 (May 12): Wegovy Weight Loss Independent of Menopausal Stage + 34,000-Woman Real-World Database Shows 42-45% Migraine and 25% Depression Risk Reduction

A second post-hoc analysis of STEP UP presented Tuesday found Wegovy 7.2 mg delivered consistent weight loss across reproductive life stages: 22.6% premenopausal, 19.7% perimenopausal, 19.8% postmenopausal, with 41.4% of premenopausal women hitting ≥25% loss. Waist-circumference reductions: 17.5%, 15.6%, 15.3% respectively. Separately, a real-world analysis of 34,000+ women showed that those taking Wegovy had a 42-45% lower migraine risk and a 25% lower depression risk starting six months in versus those on menopausal hormone therapy alone. The real-world data lands as observational signals that warrant prospective study — not as proof of causation — but reinforces the cardiovascular and quality-of-life narrative for the women's-health subgroup.